<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143004">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987284</url>
  </required_header>
  <id_info>
    <org_study_id>SMR-2271</org_study_id>
    <secondary_id>2013-001227-40</secondary_id>
    <nct_id>NCT01987284</nct_id>
  </id_info>
  <brief_title>SER100 in Isolated Systolic Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serodus ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Smerud Medical Research International AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Serodus ASA</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly
      people. Much attention has recently been drawn to the strong relationship between the
      systolic blood pressure and cardiovascular morbidity.

      In previous clinical studies carried out in individuals with normal blood pressure at
      baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the
      effect on systolic blood pressure in hypertensive patients will be larger or equal to the
      fall seen in normotensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Isolated Systolic Hypertension</condition>
  <arm_group>
    <arm_group_label>SER100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER100 10 mg s.c. twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered s.c. twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER100</intervention_name>
    <arm_group_label>SER100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>N.A.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>SER100</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure &lt; 90 mmHg -
             as determined by daytime continuous ambulatory blood pressure measurement (ABPM)

          -  Male or female

          -  Age 50-80 years (both inclusive) at screening

          -  Patients must be on stable doses with one or more antihypertensives

          -  BMI &lt;32 kg/m2

          -  Written informed consent

        Exclusion Criteria:

          -  Acute myocardial infarction in the last 6 months before screening

          -  Stroke in the last 6 months before screening

          -  Uncompensated heart failure (NYHA Class IV)

          -  Angina pectoris with an anticipated need for administration of short-acting nitrates

          -  Known, severe sleep apnoea

          -  Abnormal laboratory values (i.e. &gt; 2 x upper normal limit) at screening

          -  Subjects working night shifts (11 PM to 7 AM)

          -  Participation in any other clinical trial with an investigational medicinal product
             or device within 1 month prior to randomisation.

          -  Subjects with upper arm circumference ≤24 cm or  ≥ 42 cm.

          -  Any general condition, serious disease or current evidence of any mental or physical
             disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the
             judgment of the investigator makes the subject unsuitable for enrollment, and/or may
             interfere with the study evaluations or affect subject's safety and/or may cause risk
             for poor protocol compliance

          -  Pregnant or lactating women.

          -  Female subjects of childbearing potential, or male subjects  whose female partner
             (unless post-menopausal for 1 year or surgically sterile) is unwilling to use
             adequate contraceptive measures throughout the duration of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helga Gudmundsdottir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Øivind Foss, M.Sc.</last_name>
    <phone>+472327</phone>
    <phone_ext>2000</phone_ext>
    <email>oivind.foss@smerud.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>FinnMedi Oy/Valkeakoski District Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Alanko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRST/Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilkka Kantola, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweiss University Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Kaposci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Judit Kapocsi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medi3 Innlandet</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Hoivik, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulleval University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Gudmundsdottir, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roxy Senior, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Okorie, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
